Iovance Biotherapeutics, Inc.
IOVA
$2.45
-$0.08-3.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 3.88% | -47.87% | 5.96% | 13.96% | 14.05% |
| Total Depreciation and Amortization | 7.89% | -5.32% | 4.83% | 2.61% | 9.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.27% | -39.68% | 18.02% | 0.82% | 98.81% |
| Change in Net Operating Assets | 152.13% | 53.58% | -185.19% | 65.60% | -18.93% |
| Cash from Operations | 34.96% | -41.47% | -24.29% | 40.09% | 19.50% |
| Capital Expenditure | -20.13% | -49.02% | -82.17% | -417.65% | 89.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.51% | -20.71% | 159.86% | -214.39% | 174.25% |
| Cash from Investing | -12.76% | -32.99% | 148.52% | -221.34% | 136.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -90.78% | 4,571.03% | -93.39% | -68.65% | -22.42% |
| Repurchase of Common Stock | 91.07% | -541.36% | 85.98% | -527.70% | 78.73% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -90.77% | 6,106.80% | -94.50% | -72.55% | -21.05% |
| Foreign Exchange rate Adjustments | 45.47% | 143.12% | -194.01% | 1,102.40% | 74.54% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -170.78% | 215.48% | 24.90% | -168.33% | 332.16% |